Glycosmedia - an international diabetes news service from the UK
  Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study
  24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced (Primary Care Diabetes)
  Patterns and trends in insulin intensification among patients with type 2 diabetes: A systematic review
  Guidelines recommend insulin intensification over time to achieve HbA1c targets ... The paucity of available studies prevented a comprehensive understanding of patterns and trends in insulin intensification. Such information is needed to assess the quality of pharmacologic care for patients with T2DM (Primary Care Diabetes)
  Insulin pumps (CSII) and cardiovascular diseases and mortality in the Swedish national diabetes register
  This large prospective observational study showed risk reductions of around 5% for cardiovascular diseases and mortality with CSII compared to insulin injections in patients with type 1 diabetes followed for 6 years (Presentation Abstract, EASD)
  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
  This study provides the most definitive quantification to date of an excess risk of pancreatic cancer among diabetics. It also shows that a 30% excess risk persists for more than two decades after diabetes diagnosis, thus supporting a causal role of diabetes in pancreatic cancer. Oral antidiabetics may decrease the risk of pancreatic cancer, whereas insulin showed an inconsistent duration–risk relationship (Annals of Oncology)
  Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
  Although S7 cells are not fully equivalent to mature beta cells, their capacity for glucose-responsive insulin secretion and rapid reversal of diabetes in vivo makes them a promising alternative to pancreatic progenitor cells or cadaveric islets for the treatment of diabetes (Nature Biotechnology)
  High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN
  High-intensity statin therapy alters the progressive nature of diabetic coronary atherosclerosis, yielding regression of disease in diabetic and nondiabetic patients (Diabetes Care)
  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
  GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes (The Lancet)
  Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy
  Dual inhibition of SGLT1/SGLT2 with LX4211 produced significant dose-ranging improvements in glucose control without dose-increasing glucosuria and was associated with reductions in weight and systolic BP in metformin-treated type 2 diabetes (Diabetes Care)
  Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee
  Saxenda®, the intended brand name for liraglutide 3 mg, is a once-daily human GLP-1 analogue for the treatment of obesity (Novo Nordisk)
  Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes
  Chamomile tea significantly decreased concentration of HbA1C, serum insulin levels, insulin resistance, total cholesterol, triglyceride, and low-density lipoprotein cholesterol compared with control group (Journal of Endocrinological Investigation)
  Tweetchat - How can pharma meet the need for new diabetes drugs in cash-strapped healthcare markets?
  Experts will be discussing this issue in a Tweetchat, hosted by PMLiVE and M3, the global provider of technology services in healthcare. From noon to 1pm (UK time) on Thursday September 25th you will be able to follow the discussion live on Twitter using the hashtag #M3diabetes and (should you want to) you are invited to join in with your own questions and comments.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.

Diabetes Weekly News Update - it's FREE!

Subscribe to our free weekly e-mail Please click here if you would like to subscribe to our free weekly e-mail.

Gold Sponsors


Our sponsors have provided unrestricted educational grants for the running of this website. None of these companies have any input to, or editorial control over the content of this website.


The first glucose monitoring device to support insulin therapy management with estimated HbA1c

The first glucose monitoring device to support insulin therapy management with estimated HbA1c.

The Diabetes Times

An online newspaper for the diabetes community.


The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Book and Product Reviews

Book ReviewsA selection of book and product reviews written by the contributing editors of Glycosmedia.

Read the Reviews >>

FREE Glycosmedia iPhone and iPad App

FREE iPhone AppThe Glycosmedia App for iPhone and iPad is now available to download FREE from the iTunes store via this link.

Recommend Glycosmedia
Recommend Glycosmedia
Sponsorship and Advertising

Why sponsor Glycosmedia? >> click here

If you are interested in sponsorship or advertising opportunities with Glycosmedia then please contact the editor-in-chief Jim Young to discuss the options:


© Copyright Glycosmedia Partnership

Site by Wired up Wales